Press Releases
Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
May 12, 2022
Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022
May 12, 2022
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer
May 09, 2022
Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia
May 03, 2022
Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results
Mar 24, 2022
Displaying 16 - 20 of 71